<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03442400</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 17-695</org_study_id>
    <nct_id>NCT03442400</nct_id>
  </id_info>
  <brief_title>A Prospective Study of Fractional Flow Reserve Assessment of Intermediate Coronary Stenoses in Severe Aortic Stenosis</brief_title>
  <official_title>A Prospective Study of Fractional Flow Reserve Assessment of Intermediate Coronary Stenoses in Severe Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Volcano Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary artery blockages can reduce blood flow to the heart muscle. Fractional flow reserve&#xD;
      (iFR or FFR) assessment is an invasive tool used to determine how much blood flow is reduced.&#xD;
      The investigators will perform iFR/FFR on all intermediate coronary stenoses using standard&#xD;
      practice, immediately before (at the time of) transcatheter aortic valve replacement (TAVR)&#xD;
      and after successful TAVR. The investigators will compare pre- and post-TAVR iFR/FFR values,&#xD;
      and assess short-term outcomes. The investigators hypothesize that iFR/FFR values will be&#xD;
      consistently and significantly higher pre-TAVR in comparison with post-TAVR for the same&#xD;
      lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to determine whether iFR assessment gives a valid assessment of&#xD;
      coronary hemodynamics in patients with severe aortic stenosis.&#xD;
&#xD;
      Several factors confound the interpretation of fractional flow reserve (FFR) in patients with&#xD;
      severe aortic stenosis (AS) and intermediate severity coronary stenoses, and the widely&#xD;
      accepted cut-off value of 0.80 may not be applicable to this patient population. Coronary&#xD;
      flow reserve is known to be attenuated under conditions of left ventricular hypertrophy and&#xD;
      severe AS, with one study showing improvement in coronary flow reserve after aortic valve&#xD;
      replacement. Left ventricular hypertrophy produces fixed resistance secondary to external&#xD;
      compression of the coronary microcirculation. This potentially results in failure to achieve&#xD;
      maximal hyperemia with adenosine and can lead to false negative FFR results. Neurohormonal&#xD;
      influences in aortic stenosis can further attenuate vasodilator response and potentially&#xD;
      result in false negative FFR values. Both of these conditions result in the potential&#xD;
      deferral of lesions which may have been hemodynamically significant in the absence of severe&#xD;
      AS. At present, there are no studies which have demonstrated validity of FFR measurement in&#xD;
      patients with severe AS. Here, the investigators propose a prospective study of iFR/FFR in&#xD;
      patients with AS and indeterminate coronary lesions undergoing TAVR to understand the&#xD;
      hemodynamic consequences of AS on iFR/FFR. The investigators hypothesize that iFR/FFR values&#xD;
      will be consistently and significantly higher pre-TAVR in comparison with post-TAVR for the&#xD;
      same lesions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">February 14, 2018</start_date>
  <completion_date type="Actual">August 10, 2021</completion_date>
  <primary_completion_date type="Actual">August 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A single group of patients with severe aortic stenosis and intermediate coronary stenoses will undergo coronary physiology assessment with iFR/FFR before and after transcatheter aortic valve replacement.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>iFR/FFR</measure>
    <time_frame>Immediately prior to transcatheter aortic valve replacement, during the index procedure</time_frame>
    <description>Hemodynamic significance of a coronary stenosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pd/Pa (ratio of the pressure distal to a coronary stenosis and the pressure in the aorta)</measure>
    <time_frame>Immediately prior to transcatheter aortic valve replacement, during the index procedure</time_frame>
    <description>Hemodynamic significance of a coronary stenosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>iFR/FFR</measure>
    <time_frame>Immediately after transcatheter aortic valve replacement, during the index procedure</time_frame>
    <description>Hemodynamic significance of a coronary stenosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pd/Pa (ratio of the pressure distal to a coronary stenosis and the pressure in the aorta)</measure>
    <time_frame>Immediately after transcatheter aortic valve replacement, during the index procedure</time_frame>
    <description>Hemodynamic significance of a coronary stenosis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Coronary Artery Stenoses</condition>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>FFR/iFR arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volcano iFR/FFR Verrata Plus coronary pressure/flow wire</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Volcano iFR/FFR Verrata Plus coronary pressure/flow wire</intervention_name>
    <description>We will measure the degree of flow-limitation of intermediate severity coronary steonses using the iFR/FFR Verrata Plus coronary pressure/flow wire before and after transcatheter aortic valve replacement.</description>
    <arm_group_label>FFR/iFR arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients who have coronary stenoses between 40-70% severity and who have severe&#xD;
             aortic stenosis undergoing TAVR work-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with documented intraprocedural hemodynamic instability, shock, or major&#xD;
             adverse event (myocardial infarction, aortic rupture/dissection, stroke, left&#xD;
             ventricular perforation, cardiac arrest).&#xD;
&#xD;
          -  Contraindication to adenosine, presence of cardiogenic shock, presence of acute&#xD;
             coronary syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir R Kapadia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Samir Kapadia</investigator_full_name>
    <investigator_title>Director, Sones Catheterization Laboratories</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Stenoses</keyword>
  <keyword>Aortic Stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

